Resverlogix Corp. is a clinical stage cardiovascular company, which engages in the research and development of novel biopharmaceuticals for the treatment of grievous diseases. The company is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix's epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including, cancer, autoimmune and neurodegenerative disorders. Resverlogix was founded by Donald J. McCaffrey and Norman C. W. Wong on April 25, 2003 and is headquartered in Calgary, Canada.